Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

ificant long-term revenue for the Company while building value for our shareholders," said Juergen Engel, Ph.D., President and CEO of AEterna Zentaris.

About the Phase 3 Program with Cetrorelix in BPH

Cetrorelix pamoate is currently in three Phase 3 trials involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe.

The first multi-center efficacy study for which patient recruitment was completed in April 2008, is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

The second multi-center Phase 3 efficacy study for which patient recruitment was completed in October 2008, involves 420 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include ch
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... May 16, 2013  HealthSparq, a trusted provider ... nation,s largest regional health plans, will debut a ... Plans (AHIP) Institute 2013 conference on June 13. ... showing how health insurance companies across the country ... and marketplace demands for increased healthcare transparency. ...
(Date:5/16/2013)... FL (PRWEB) May 16, 2013 As the ... to showcase their favorite Spring looks. While most make a ... season. Unfortunately, many women find the warmer weather mixes makeup ... women cope with the onset of acne during warmer months, ... from female acne treatment users the best ways to deter ...
(Date:5/16/2013)... , May 16, 2013 /PRNewswire/ ... market research report is available in ... Diagnostic Cardiac Biomarkers for Acute Coronary ... Forecasts http://www.reportlinker.com/p01182969/MediPoint-Diagnostic-Cardiac-Biomarkers-for-Acute-Coronary-Syndromes---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... for Acute Coronary Syndromes - APAC ...
(Date:5/16/2013)... May 16, 2013 Dr. Stephen Y. ... tutorial titled “Nanoimprint Lithography and Applications” at IEEE Nano ... Nanoimprint, invented in 1995 by Chou, is becoming one ... a unique combination of sub-10 nm resolution, large area, ... is impacting both R&D and manufacturing in a broad ...
Breaking Biology Technology:HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 3MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 5MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 6MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 7MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 8Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013 2
... , EATONTOWN, N.J., July 29 ... in the emerging field of biologic products for regenerative healing, ... the Company, the French regulatory agency, afssaps, rescinded its December ... of tissue products processed from donors procured by TB OsteoCentre ...
... , VAN BUREN TWP., Mich. , ... of Ricardo plc, the leading independent provider of technology, product ... and new energy industries, has announced that the company is ... low carbon engine technologies. With the environmental demand to reduce ...
... , , SAN DIEGO, ... NBIX ) today announced new six month safety and ... using its proprietary, orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor ... previously reported six month (Petal Study) and three month ...
Cached Biology Technology:Osteotech Resumes Shipments of Bulgarian Tissue 2Osteotech Resumes Shipments of Bulgarian Tissue 3Ricardo Launches Consortium to Evaluate Lubricant Challenges of Future Low Carbon Engine Technologies 2Ricardo Launches Consortium to Evaluate Lubricant Challenges of Future Low Carbon Engine Technologies 3Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis 2Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis 3Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis 4
(Date:5/16/2013)... MD FASEB MARC (Maximizing Access to Research ... for The Society for Developmental Biology (SDB) 72nd ... 2013. These awards are meant to promote the ... groups into the mainstream of the basic science ... scientists at the SDB 2013 Annual Meeting. , ...
(Date:5/16/2013)... involved in neurodegenerative disease also plays a critical role ... , In a study of the common fruit fly, ... clock responsible for sleeping and waking on a 24-hour ... fly,s sleep-wake cycle is disturbed, making waking up on ... The discovery is particularly interesting because mutations in the ...
(Date:5/16/2013)... The relationship between the heritable risk for ... clear. Schizophrenia is commonly associated with cognitive impairments ... that reduced IQ may be linked to the ... ability may precede the onset of schizophrenia symptoms. ... relatives of people diagnosed with schizophrenia. , In ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 2Genetic risk for schizophrenia is connected to reduced IQ 2
... cancer is known to occur typically in older men. Yet ... of diagnosis. Scientists assume that these cases might be the ... cancer might be a subtype which is characterized by a ... is likely that these include a number of what are ...
... production and a growing need to find cost-effective livestock feedstuff ... the use of glycerin in swine diets. This ... Mendoza, was published in the Journal of Animal Science and ... glycerin and achieve similar performance to a conventional corn:soybean diet. ...
... The National Cancer Institute estimates that more than ... and more than 36,000 died from the disease. ... oncogene is mutated in virtually all pancreatic cancers, scientists ... pathways in humans, which make it difficult to pinpoint ...
Cached Biology News:Uncovering the genetics of prostate cancer 2Uncovering the genetics of prostate cancer 3Uncovering the genetics of prostate cancer 4University of Illinois study confirms glycerin as a feasible feedstuff for swine 2Roundworm unlocks pancreatic cancer pathway 2
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
... for all tested applications). ... from within residues 500 to the C-terminus of ... is proprietary) (Peptide available as ... ID: 51043 Swiss Protein ...
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
...
Biology Products: